For distributorsGrow the UBE category with us

A defendable territory, a growing category and a partner who brings the surgeon-facing demand.

UBE is not just another endoscopy. It is a defined European category.

01

A growing category in your defendable territory

02

Lower competition than in monoportal endoscopy

03

A surgical society with its own network

04

Predictable economics

A partnership built around demand

UBE has its own surgical society, its own diploma and its own surgeon network — all of which Nexon has helped to build. When you partner with us, you get a defendable territory in a category where competition is structurally less intense than in monoportal endoscopy.

We bring the surgeon-facing demand; you close. The economics are predictable, the training is available, and the volume curve is steep.

Book a 30-minute conversation →

Voices from the Nexon Distributors

Frank Middeke on adopting UBE biportal endoscopy in everyday spine care
Spine surgery evolves through different lifecycles. Open surgery established the foundation, followed by microsurgery and minimally invasive approaches. We are now entering the next phase: the endoscopic era, with UBE positioned to become an important standard in everyday spine care. This transition requires more than adopting a new technique. Surgeons and their teams need to develop new skills, confidence, and clinical routines. Nexon supports the complete adoption journey by combining the EnSight UBE platform with structured education, mentoring, and practical support.

Frank Middeke, CEO Komid AG Germany

Hrvoje Dudukovic, MedConnect Croatia, Nexon Medical distribution partner for UBE biportal endoscopy
Nexon does not simply provide us with products and expects us to develop the market alone. We work together on surgeon engagement, education, clinical activities, and the support needed after the first cases. This collaborative model helps us build trust with surgeons and hospitals while creating sustainable demand. Nexon’s success model aligns our teams around the same objective: developing UBE for the long term.

Hrvoje Dudukovic, MedConnect, Croatia